Mario Negri Institute for Pharmacological Research
Italian pharmacological research institute
The Mario Negri Institute for Pharmacological Research is a prominent pharmacological research institute in Italy, dedicated to the study of biomedical sciences and the development of new therapeutic strategies. Founded in 1961 by Silvio Garattini, the institute is named after Mario Negri, a philanthropist who supported scientific research.
History[edit | edit source]
The Mario Negri Institute was established in Milan, Italy, with the aim of advancing pharmacology and toxicology research. Over the years, it has expanded its facilities and research capabilities, becoming a leading center for clinical trials and epidemiological studies. The institute has played a significant role in the development of new drugs and therapies for various diseases.
Research Areas[edit | edit source]
The institute focuses on several key areas of research:
- Oncology: Investigating the mechanisms of cancer development and progression, and developing new anticancer drugs.
- Cardiovascular diseases: Studying the pathophysiology of heart disease and stroke, and exploring new treatment options.
- Neuroscience: Researching neurological disorders such as Alzheimer's disease, Parkinson's disease, and epilepsy.
- Public health: Conducting epidemiological research to understand the impact of various factors on public health and to develop preventive strategies.
Facilities[edit | edit source]
The Mario Negri Institute operates several research centers across Italy, including the main facility in Milan and additional centers in Bergamo and Ranica. These centers are equipped with state-of-the-art laboratories and technology to support advanced research activities.
Collaborations[edit | edit source]
The institute collaborates with numerous national and international organizations, universities, and research centers. These collaborations enhance the institute's research capabilities and facilitate the exchange of knowledge and expertise.
Education and Training[edit | edit source]
The Mario Negri Institute is committed to the education and training of young scientists. It offers various programs, including PhD and postdoctoral training, to foster the development of future leaders in biomedical research.
Related pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
